Sientra to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

Rhea-AI Summary

Sientra, a medical aesthetics company, will release its financial results for Q3 2021 on November 10, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss these results, with dial-in options for both domestic and international callers. Sientra specializes in innovative products tailored for plastic surgeons, including FDA-approved breast implants and advanced tissue expanders. The company emphasizes its commitment to innovation and patient care while providing valuable resources through its investor relations website.

Positive

• Scheduled release of Q3 2021 financial results could indicate transparency and communication with investors.
• Focus on proprietary innovations and partnerships enhances Sientra's market position in the medical aesthetics sector.

Negative

• None.

SANTA BARBARA, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that it will release financial results for the third quarter of 2021 after the close of trading on Wednesday, November 10, 2021. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.

The dial-in numbers are (844) 464-3933 for domestic callers and (765) 507-2612 for international callers. The conference ID is 8785834.

A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.sientra.com. The webcast will be archived on the website following the completion of the call.  

About Sientra

Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company exclusively focused on plastic surgery. The Company mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s product portfolio includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2^® breast tissue expander with patented dual-port and integral drain technology, and BIOCORNEUM^®, the #1 performing, preferred and recommended scar gel of plastic surgeons(*).

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.

^(*) Data on file

Investor Relations Contact
Leigh Salvo
ir@sientra.com

FAQ

When will Sientra release its Q3 2021 financial results?

Sientra will release its Q3 2021 financial results on November 10, 2021, after the market closes.

What time is the Sientra conference call for Q3 2021 results?

The conference call to discuss Q3 2021 financial results will take place at 4:30 p.m. ET on November 10, 2021.

How can I access the Sientra conference call?

The conference call can be accessed by dialing (844) 464-3933 for domestic callers or (765) 507-2612 for international callers, using the conference ID 8785834.

Where can I find Sientra's investor relations information?

Sientra's investor relations information is available on their website at www.sientra.com.

What products does Sientra specialize in?

Sientra specializes in medical aesthetics products, including FDA-approved breast implants and innovative tissue expanders.